Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INV-6452 in HR+/HER2- Advanced Breast Cancer and Solid Tumors
NCT07612891Phase 2Recruiting
- Sponsor
- Ionova Life Science
- Start
- Jul 2025
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of INV-6452 in breast cancer and solid tumor (2 arms), sponsored by Ionova Life Science. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Dose Range at 12 months and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
INV-6452
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT07612891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612891.